Protagonist Therapeutics Inc Stock
Protagonist Therapeutics Inc gained 1.360% today.
The stock is one of the favorites of our community with 25 Buy predictions and 1 Sell predictions.
On the other hand, the target price of 71 € is below the current price of 74.5 € for Protagonist Therapeutics Inc, so the potential is actually -4.7%.
So far the community has only identified positive things for Protagonist Therapeutics Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Protagonist Therapeutics Inc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
B****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Comments
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Jefferies Financial Group Inc. from $95.00 to $118.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Citigroup Inc. from $96.00 to $98.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at JPMorgan Chase & Co. from $68.00 to $81.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for PTGX provided by MarketBeat
News
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance
On Feb. 6, 2026, William D. Waddill, a director at Protagonist Therapeutics (NASDAQ:PTGX), exercised his stock options and immediately sold 20,000 shares, generating a transaction value of
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes
Arturo Molina, Chief Medical Officer of Protagonist Therapeutics (NASDAQ:PTGX), directly sold 9,514 shares in an open-market transaction on Jan. 20, 2026, for an approximate value of $784,700
Johnson & Johnson's M&A Strategy Is the Real Story for Investors
Recent market speculation linking Johnson & Johnson (NYSE: JNJ) to a complete acquisition of its partner, Protagonist Therapeutics (NASDAQ: PTGX), offers a valuable glimpse into a core corporate
